Verition Fund Management
SLS icon

Verition Fund Management’s SELLAS Life Sciences SLS Stock Holding History

Verition Fund Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$917K Buy
62,100
+1,800
+3% +$12.4K ﹤0.01% 1455
2026
Q1 		$255K Buy
60,300
+40,800
+209% +$183K ﹤0.01% 1853
2025
Q4 		$73.5K Buy
+19,500
New +$37.9K ﹤0.01% 3351

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Verition Fund Management's SLS Position: Q2 2026 in Review

Verition Fund Management sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 12,262 shares — an estimated $84.7K sold.

Verition Fund Management first reported a position in SLS in Q1 2026 and held it in 1 quarter. The position peaked at $51.9K in Q1 2026. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Verition Fund Management reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Verition Fund Management sold 12,262 SELLAS Life Sciences shares in Q2 2026, an estimated $84.7K.
  • Verition Fund Management first reported a position in SELLAS Life Sciences in Q1 2026 and held it in 1 quarter.
  • Verition Fund Management's SELLAS Life Sciences position peaked at $51.9K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.